Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Ltd announced a change in the substantial holding of its shares, with Paul Hopper’s voting power decreasing from 12.4% to 11.3%. This change was due to Deborah Coleman’s participation in an entitlement offer, which affected 10 million shares. The announcement highlights shifts in shareholder dynamics, potentially impacting the company’s governance and strategic decisions.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is a company operating in the biotechnology industry, focusing on the development of innovative therapies. The company is primarily engaged in creating and advancing cell therapies for cancer treatment, aiming to improve patient outcomes in the oncology market.
Technical Sentiment Signal: Buy
Current Market Cap: A$9.09M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.